CN101516339B - 制备高度结晶的治疗化合物的固体分散体的方法 - Google Patents

制备高度结晶的治疗化合物的固体分散体的方法 Download PDF

Info

Publication number
CN101516339B
CN101516339B CN2007800302086A CN200780030208A CN101516339B CN 101516339 B CN101516339 B CN 101516339B CN 2007800302086 A CN2007800302086 A CN 2007800302086A CN 200780030208 A CN200780030208 A CN 200780030208A CN 101516339 B CN101516339 B CN 101516339B
Authority
CN
China
Prior art keywords
poloxamer
therapeutic compound
therapeutic compounds
highly crystalline
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800302086A
Other languages
English (en)
Chinese (zh)
Other versions
CN101516339A (zh
Inventor
I·高希
J·斯奈德
W-Q·童
S·维帕贡塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101516339A publication Critical patent/CN101516339A/zh
Application granted granted Critical
Publication of CN101516339B publication Critical patent/CN101516339B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN2007800302086A 2006-08-16 2007-08-14 制备高度结晶的治疗化合物的固体分散体的方法 Expired - Fee Related CN101516339B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82255606P 2006-08-16 2006-08-16
US60/822,556 2006-08-16
PCT/US2007/017960 WO2008021347A2 (en) 2006-08-16 2007-08-14 Method for making solid dispersions of highly crystalline therapeutic compounds

Publications (2)

Publication Number Publication Date
CN101516339A CN101516339A (zh) 2009-08-26
CN101516339B true CN101516339B (zh) 2012-06-13

Family

ID=38657762

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800302086A Expired - Fee Related CN101516339B (zh) 2006-08-16 2007-08-14 制备高度结晶的治疗化合物的固体分散体的方法

Country Status (16)

Country Link
US (2) US20100038816A1 (https=)
EP (1) EP2054040B1 (https=)
JP (1) JP5546860B2 (https=)
KR (1) KR101462693B1 (https=)
CN (1) CN101516339B (https=)
AT (1) ATE503484T1 (https=)
AU (1) AU2007284615B2 (https=)
BR (1) BRPI0714963A2 (https=)
CA (1) CA2660086C (https=)
DE (1) DE602007013567D1 (https=)
ES (1) ES2363725T3 (https=)
MX (1) MX2009001636A (https=)
PL (1) PL2054040T3 (https=)
PT (1) PT2054040E (https=)
RU (1) RU2454220C2 (https=)
WO (1) WO2008021347A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
MX2010011962A (es) * 2008-04-30 2010-11-30 Novartis Ag Proceso continuo para hacer composiciones farmaceuticas.
EP2327706A1 (en) 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN102525879B (zh) * 2010-12-31 2015-01-21 正大天晴药业集团股份有限公司 制备阿瑞匹坦固体分散组合物的方法
BR112016021739B1 (pt) * 2014-03-25 2021-11-03 Genentech, Inc Método para preparar um poloxâmero para uso em um meio de cultura de célula
CN107001322B (zh) 2014-12-18 2020-07-28 默沙东公司 用于药物制剂的组合物
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
CN108024939B (zh) 2015-08-20 2024-06-07 联合利华知识产权控股有限公司 包封的内酰胺
ES2758300T3 (es) 2015-08-20 2020-05-05 Unilever Nv Solubilidad de lactama mejorada
EP3337451B1 (en) 2015-08-20 2018-12-26 Unilever PLC Improved lactam solubility
CN107848968B (zh) 2015-08-20 2021-06-18 荷兰联合利华有限公司 从乙醛酸制备内酰胺的方法
WO2017029093A1 (en) 2015-08-20 2017-02-23 Unilever Plc Improved lactam solubility
CN107920976A (zh) 2015-08-20 2018-04-17 荷兰联合利华有限公司 改善的内酰胺溶解度
BR112018003082B1 (pt) * 2015-08-20 2021-12-14 Unilever Ip Holdings B.V. Lactama em uma dispersão sólida, método de produção de uma composição compreendendo uma lactama e método de formação de lactama em uma dispersão sólida
JP7021182B2 (ja) * 2016-03-24 2022-02-16 ロケート・バイオ・リミテッド 足場材料、方法および使用
MX383740B (es) * 2016-05-13 2025-03-14 Merck Patent Gmbh Composición de extrusión fundida en caliente que usa un excipiente compresible directo como plastificante.
CN111615389A (zh) 2018-02-01 2020-09-01 科尔沃斯制药股份有限公司 药物调配物
EP3520782A3 (en) * 2018-02-01 2019-11-13 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations containing adenosine a2a receptor antagonists
CN113573712A (zh) 2019-02-18 2021-10-29 斯莱班克制药有限责任公司 尼洛替尼的药物组合物
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
CN114796149A (zh) * 2022-04-27 2022-07-29 苏州中化药品工业有限公司 一种高生物利用度的双醋瑞因胶囊剂及其制备方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024494A1 (en) * 2004-08-31 2006-03-09 Novartis Ag Use of midostaurin for treating gastrointestinal stromal tumors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
US5837714A (en) * 1997-03-03 1998-11-17 Sanofi Solid pharmaceutical dispersions
ATE232087T1 (de) * 1997-10-27 2003-02-15 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
EP1372611B1 (en) 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
HU229938B1 (en) * 2001-05-03 2015-01-28 Hoffmann La Roche Pharmaceutical dosage form of amorphous nelfinavir mesylate
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
US6756381B2 (en) * 2002-02-21 2004-06-29 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide
GB0315012D0 (en) * 2003-06-27 2003-07-30 Leuven K U Res & Dev Zeotiles
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
KR20060101762A (ko) * 2003-11-21 2006-09-26 쉐링 코포레이션 포스포디에스테라제 ｖ 억제제 제형
US7498309B2 (en) * 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
CN102127057A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
US20050288481A1 (en) * 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
JO2897B1 (en) * 2004-11-05 2015-09-15 نوفارتيس ايه جي Organic compounds
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
WO2007068615A2 (en) * 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation
BRPI0622054B8 (pt) * 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US8258137B2 (en) * 2008-01-29 2012-09-04 Katholieke Universiteit Leuven Process for release of biologically active species from mesoporous oxide systems
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
CN107898791A (zh) * 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
EP2618846A1 (en) * 2010-09-24 2013-07-31 Mallinckrodt LLC Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers
US9295673B2 (en) * 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024494A1 (en) * 2004-08-31 2006-03-09 Novartis Ag Use of midostaurin for treating gastrointestinal stromal tumors

Also Published As

Publication number Publication date
MX2009001636A (es) 2009-02-23
WO2008021347A3 (en) 2008-08-07
WO2008021347A2 (en) 2008-02-21
PL2054040T3 (pl) 2011-09-30
CA2660086A1 (en) 2008-02-21
EP2054040B1 (en) 2011-03-30
ES2363725T3 (es) 2011-08-12
DE602007013567D1 (de) 2011-05-12
US8641948B2 (en) 2014-02-04
KR20090042961A (ko) 2009-05-04
PT2054040E (pt) 2011-06-30
US20120190667A1 (en) 2012-07-26
JP2010500411A (ja) 2010-01-07
AU2007284615B2 (en) 2011-10-27
RU2454220C2 (ru) 2012-06-27
BRPI0714963A2 (pt) 2013-07-30
ATE503484T1 (de) 2011-04-15
AU2007284615A1 (en) 2008-02-21
RU2009109357A (ru) 2010-09-27
KR101462693B1 (ko) 2014-11-17
US20100038816A1 (en) 2010-02-18
CA2660086C (en) 2014-09-16
CN101516339A (zh) 2009-08-26
JP5546860B2 (ja) 2014-07-09
EP2054040A2 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
CN101516339B (zh) 制备高度结晶的治疗化合物的固体分散体的方法
CN102076329B (zh) 熔融制粒法
JP2013100369A (ja) 一時可塑剤を用いる医薬組成物の製造法
US20090148522A1 (en) Heated roller compaction process for making pharmaceutical compositions
US20090023754A1 (en) Modified release famciclovir pharmaceutical compositions
RU2723255C2 (ru) Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы
WO2018093289A1 (ru) Пероральная твердая лекарственная форма и способ ее получения
MX2008005880A (en) Process for making pharmaceutical compositions with a transient plasticizer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Basel, Switzerland

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120613

CF01 Termination of patent right due to non-payment of annual fee